NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

Veracyte, Inc. (VCYT) Stock Analysis

Veracyte, Inc. (VCYT) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VCYT

$46.22

+$1.43 (+3.19%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VCYT with… →

VCYT Key Statistics

As of Oct 21, 2026
Trading
Open
$44.17
Previous Close
$44.79
Day's Range
43.90–46.42
52-Week Range
29.46–60.91
Volume
812.06K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.95
Valuation
Market Cap
$3.72B
P/E Ratio
33.01
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
23.76
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.61
EPS (ttm)Profit attributable to each share over the last twelve months.
1.40
Financials (FY)
Revenue (FY)
$517.15M+16.01%
Net Income (FY)
$66.35M+174.89%
Profit marginThe share of revenue left as profit after all costs and taxes.
20.37%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
80.39M
1-Year Return
+28.03%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
1.35M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VCYT closed at $46.22, +28.03% over 1 year.

Veracyte, Inc. (VCYT) has a market capitalization of $3.72B.

In fiscal 2025, VCYT reported revenue of $517.15M.

VCYT Stock Return by Calendar Year

Veracyte, Inc. (VCYT) 10-year return: what $10,000 became

1 year
$10,000 $12,803
+28.03%
5 years
$10,000 $9,933
−0.67%
10 years
$10,000 $56,921
+469.21%

If you had invested $10,000 in Veracyte, Inc. (VCYT) 10 years ago, at the close on October 21, 2016, it would have been worth $56,921 at the close on October 21, 2026: +469.21% in total, +18.99% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+9.79%
2025+6.31%
2024+43.95%
2023+15.93%
2022−42.40%
2021−15.82%
2020+75.29%
2019+121.94%
2018+92.65%
2017−15.63%
2016 (partial year)+54.80%

As of October 21, 2026.

VCYT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$517.15M$66.35M12.8%
2024$445.76M$24.14M5.4%
2023$361.05M−$74.40M−20.6%
2022$296.54M−$36.56M−12.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$517.15M$362.53M$78.28M$66.35M12.8%
2024$445.76M$298.15M$19.51M$24.14M5.4%
2023$361.05M$229.68M−$17.45M−$74.40M−20.6%
2022$296.54M$175.68M−$35.34M−$36.56M−12.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VCYT Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricVCYTDiagnostics & Research medianvs median
P/E33.0137.5912% below
P/S ratio6.615.2327% above
Profit margin20.37%−0.93%21.3 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Veracyte, Inc. (VCYT) is capitalised at $3.72B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 755.

VCYT last closed at $46.22 on October 21, 2026. That is +$1.43 (+3.19%) against the previous close. Over the past 52 weeks the price has ranged from $29.46 to $60.91. The latest close sits 56.92% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $517.15M. That is +16.01% against the prior fiscal year, when revenue was $445.76M. The same year closed with net income of $66.35M. That is +174.89% against the prior fiscal year. Profit margin runs at 20.37%. That is 21.3 percentage points above the Diagnostics & Research median of −0.93%. Trailing earnings per share are 1.4.

Across the 4 fiscal years on file, revenue moves from $296.54M in 2022 to $517.15M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

VCYT trades at a trailing price-to-earnings ratio of 33.01. That is 12.17% below the Diagnostics & Research median of 37.59. On forward earnings the ratio is 23.76. The price-to-sales ratio is 6.61. On price-to-sales that is 26.51% above the Diagnostics & Research median of 5.23. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.95. Annualized volatility over the trailing 10 years is 62.76%. The trailing one-year total return is +28.03%. Across 10 years the annualized return works out at +18.99%.

Growth & Income

No dividend is on file for VCYT.

So far in 2026 the total return is +9.79%. Across the complete calendar years on file, 2019 returned +121.94% and 2022 returned −42.40%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Veracyte, Inc. (VCYT) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Veracyte, Inc. VCYT $3.72B 33.0
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. Veracyte, Inc. trades at a P/E of 33.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Visit website →